Research Article

Sero prevalence of anti-tissue transglutaminase in patients having sign symptoms of celiac disease: A cross sectional study from Peshawar, Pakistan

Shehryar Ahmad^{1,2*}, Naseem Akhtar Gill¹, Farmanullah¹, Irum Naz³, Nasir Ali², Muhammadullah Afridi¹, Naqash Ahmad² and Nihal Ahmad⁴

1. Rehman college of Allied Health Sciences

2. College of Medical Technology, Bacha Khan Medical College, Mardan-Pakistan

3. National College University System-Pakistan

4. Clinical Technologist at Rahman Medical Institute Peshawar-Pakistan

*Corresponding author's email: shery9444@gmail.com

Citation

Shehryar Ahmad, Naseem Akhtar Gill, Farmanullah, Irum Naz, Nasir Ali, Muhammadullah Afridi, Naqash Ahmad and Nihal Ahmad. Sero prevalence of anti-tissue transglutaminase in patients having sign symptoms of celiac disease: A cross sectional study from Peshawar, Pakistan. Pure and Applied Biology. Vol. 10, Issue 1, pp280-284. <http://dx.doi.org/10.19045/bspab.2021.100029>

Received: 23/06/2020

Revised: 24/08/2020

Accepted: 01/09/2020

Online First: 17/09/2020

Abstract

Gluten sensitive enteropathy or more commonly known as celiac disease is one of the autoimmune disorder affecting 1% of the individual globally. It is one of the common gastrointestinal disorder in Peshawar, Pakistan and there is scarce of literature available on its prevalence hence this study was aim to determine the seroprevalence of Anti Tissue Transglutaminase (tTG) in patient suspected of celiac disease and subtype of antibody i.e IgG-IgA contributed towards its seroprevalence. A cross sectional study was conducted on 639 patients having sign symptoms of celiac disease visiting to Rahman medical Institute Peshawar, Pakistan in 2018. Convenient sampling technique were used for selection of samples and screening was done by testing serum Anti tTG IgG and Anti tTG IgA antibody level by Alegria Enzyme linked Immune Sorbent Assay (ELISA) technology. Chi-square test were performed for association between the categorical variable and p value of <0.05 was considered statistically significant. Out of total 639 patients, 57 patients were positive for Anti tTG antibodies and the highest count was observed in age group 0- 20 with frequency of 49 patients. Chi square test reveals no statistically significant difference between gender and seroprevalence of Anti-tTG with a P value of <0.05. The seroprevalence of Anti-tTG were high among age ranges from 1 to 20 years. Anti tTG IgG-IgA contribute for screening of celiac disease, however small bowel biopsy is required for confirmation of diagnosis.

Keywords: Antitissue transglutaminase; Antibodies; Celiac disease; ELISA; Seroprevalence

Introduction

Celiac disease also known as gluten sensitive enteropathy is one of the most common autoimmune disease

characterized by both intestinal (diarrhoea, bloating, constipation) and extra intestinal (anemia, osteoporosis, depression, weight loss) clinical symptoms [1, 2]. Celiac

disease cases were frequent and still considered uncommon in different parts of world. Gluten a family of protein found in wheat, barley, spelt and rye. The exposure of gluten in those having celiac disease can damage the microvilli by eliciting immune response. Genetic mutations involved in celiac disease are HLA-DQ2 and HLA-DQ8 a cellular protein which triggers an immune response [3]. Gluten free diet is recommended in order to render the symptoms and healing of intestinal mucosa [4]. The clinical manifestation remains silent or may vary in form of only extra intestinal presentation. In Countries related to European region celiac disease is one of most common encountered disorder affecting 0.5 to 1% of general population. In Netherlands the overall prevalence of celiac disease was reported to be 0.02% in adults [5]. An Italian and finnish studies also reported overall prevalence of 1.06% and 1% of celiac disease. Various screening studies reported the silent form of celiac disease which is more frequent and results in severe complication in the form metabolic bone disorder or immune conditions if not treated early or delay diagnosis. A reliable and accurate detection is always need of time and is difficult in case of celiac disease because most of the time patients have atypical symptoms which are mild in nature. Antibody levels are measured using ELISA technique by measuring serum anti tTG IgG and IgA level which have been used as a sensitive tool for screening of celiac disease. Various other antibodies such as anti-EM antibody (EMA) and gliadin (AGA) levels are also measured for screening purposes [6, 7]. There is scarce of literature available on seroprevalence of celiac disease in this part of world , therefore the study was aim to determine the prevalence of Anti tTG in patients having sign symptoms of celiac disease and their pattern in order to reveal age and gender differences.

Materials and Methods

A cross sectional study was conducted in Rehman medical institute between February-2018 to August-2018. A total of 639 patients having sign symptoms of celiac disease from paediatric and gastroenterology department were included in study irrespective of gender and age. About 3 to 5 ml of blood was collected in a gel vacutainer and centrifuged for obtaining serum. The protocol of study was screening of Anti tTG level using ELISA technology in serum sample on Alegria analyzer. All samples were kept store at -20C for other test or for delayed analysis. No samples were reanalyzed after frozen and thawing more than once and check for lipemia and haemolysis. Alegria ELISA technology involves barcoded 8 well microstrips for quantitative determination. Microstrips contain Tetramethylbenzidine (TMB) substrate, sample buffer and enzyme conjugate. Using Sensotronic Memorized Calibration (SMC) Technology, information about assay, calibration, lot specific data are present on barcode on each strip. A value of >10IU/ml for both IgG and IgA level were considered as positive. Quality control procedure also involves 8 well strip having positive sample, enzyme conjugate, substrate and have individual barcode. Data were analyzed using SPSS version 19 and displayed in the form of tables and graphs. Chi square test of association were applied to find out association between the categorical variable and p-value of <0.05 were considered statistically significant.

Results

A total of 639 patients were screened for both Anti tTG IgG-IgA level. 57(8.9%) patients were found positive for both antibodies and 582 patients were negative for both antibodies. Out of 57 positive samples 26 samples were positive for anti tTG-IgG while 31 for anti tTG- IgA as shown in (Table 1).

Out of 381 male 31 were positive for AntitTG while 350 patients were negative. There is no statistical significant

association found between gender and seroprevalence of Anti tTG antibodies. ($p=0.398327 > 0.05$) as shown in (Table 2). In (Table 3 & 4) demonstrate difference between age group and Antibody sub type

with no statistical significant relation found for both Anti tTG IgA-IgG and different age groups.

Table1. Frequency distribution of positive cases

Antibody type	Frequency	Percentage
Anti tTG-IgG positive	26	45.61%
Anti tTG-IgA positive	31	54.39%

Table 2. Gender wise Anti tTG distribution (n=639)

Gender	Anti tTG Negative	Anti tTG Positive	Marginal Row Totals
Male	350 (347.01) [0.03]	31 (33.99) [0.26]	381
Female	232 (234.99) [0.04]	26 (23.01) [0.39]	258
Marginal Column Totals	582	57	639 (Grand Total)

The chi-square statistic is 0.7134. The p-value is .398327. Not significant at $p < .05$

Table 3. Relationship between Age groups and Anti tTG-IgG

Age groups	Anti tTG-IgG positive	Anti tTG-IgG Negative	Row Totals
Age group 1 – 20	21 (18.92) [0.23]	444 (446.08) [0.01]	465
Age group 21 – 40	4 (4.64) [0.09]	110 (109.36) [0.00]	114
Age group 41 – 60	0 (1.71) [1.71]	42 (40.29) [0.07]	42
Age group 61 – 80	1 (0.73) [0.10]	17 (17.27) [0.00]	18
Column Total	26	613	639

The chi-square statistic is 2.2133. The p-value is .52934. The result is not significant at $p < .05$

Table 4. Relationship between Age groups and Anti tTG-IgA

Age groups	Anti tTG-IgA positive	Anti tTG-IgA Negative	Row Totals
Age group 1 – 20	28 (22.56) [1.31]	437 (442.44) [0.07]	465
Age group 21 – 40	3 (5.53) [1.16]	111 (108.47) [0.06]	114
Age group 41 – 60	0 (2.04) [2.04]	42 (39.96) [0.10]	42
Age group 61 – 80	0 (0.87) [0.87]	18 (17.13) [0.04]	18
Column Total	31	608	639

The chi-square statistic is 5.6555. The p-value is .129628. The result is not significant at $p < .05$

Discussion

Celiac diseases have several clinical presentation ranges from mild, latent, atypical to potential involving predominantly those with predisposing factors. With advancement to availability of diagnostic facilities the prevalence of celiac disease is high comparable to previously thought. The major factor contributed for high prevalence is increase awareness of several clinical manifestation

of celiac disease [8, 10]. Serologic testing using anti tTG have facilitated celiac diagnosis for prompt diagnosis and have higher level of sensitivity and specificity reported [11, 12]. European society of paediatric gastroenterology and Nutrition also recommend immunological markers for celiac disease diagnosis in order to limit the intervention of intestinal biopsies if tTg IgA >10 times upper limit of normal

along with concordant agreement of family [13].

In our study the overall prevalence of celiac disease were 8.9%. A similar study conducted by Saberi-Firouzi, *et al.* [14] reported overall prevalence of 0.5% (1:180) which is low comparable to our finding. Their high sample size may contribute for low prevalence. Study conducted in northern and southern Iran on gluten sensitive enteropathy reported 29 cases positive for Anti tTG antibody Gursoy *et al.* [15] reported 1.76% prevalence of celiac disease. Gursoy *et al.* [6] however another study from turkey reported similar prevalence of 8.3% in those having predisposing factor such as short stature using endoscopic small intestinal biopsy respectively. Muhammad *et al.* [16] also reported similar finding of 7.1% overall prevalence of celiac disease. The serological diagnosis have importance in detection of celiac disease using different immunological markers however the true prevalence will not revealed until subjected to histopathological findings.

Similar finding were also reported by Pakistani study [17] with a prevalence of 11.7% for anti tTG IgA antibodies with predominance of higher prevalence in children. Our study also shows a similar pattern of age related seroprevalence with higher frequency found in age group 1-20 years respectively. This shows a concordant pattern of prevalence in this geographical area of world.

Infancy and childhood may contribute for larger prevalence of celiac disease. Our finding also revealed lower prevalence of adulthood and higher frequency of childhood disease. Various studies reported higher percentage of childhood disease distribution and decrease percentage stated in adulthood. [17, 18] We found higher seroprevalence of Anti tTG IgA compared to Anti tTG IgG. Similar finding were also reported by Gillet *et al.* [19].

Anti-tTG IgA-IgG contribute significantly in immunological detection of celiac

disease however other specific immunological markers such as anti-endomysial antibody and small intestinal biopsy remains gold standard for staging ,grading of disease and to rule out false positive result associated with other autoimmune pathologies. In our setting gluten is present in mostly edible food and only therapeutic strategy is prevention from diet containing gluten. A larger scale study is needed for revealing of economic burden contribute by gluten free diet and to figure out the true histopathological characteristics of celiac disease with respect to its grading.

Conclusion

We conclude that anti tTG- Antibody is high in childhood as compared to other age groups. Gender revealed no significant association with seroprevalence of disease. Serological along with histopathological investigations may contribute accurate and more reliable diagnosis.

Authors' contributions

Conceived and designed the experiments: S Ahmad, NA Gill & F ullah, Performed the experiments: NA Gill & F Ullah, Analyzed the data: S Ahmad, N Ali, M Afridi, N Ahmad, NQ Ahmad & I Naz, Contributed materials/ analysis/ tools: S Ahmad, NA Gill, N Ahmad, NQ Ahmad, N Ali & I Naz, Wrote the paper: S Ahmad.

References

1. Murray JA, Watson T, Clearman B & Mitros F (2004). Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. *The Am J of Clin-Nutr* 79(4): 669–673.
2. Dickey W & Kearney N (2006). Overweight in celiac disease: prevalence, clinical characteristics, and effect of a gluten-free diet. *Am J of Gastro* 101(10): 2356–2359.
3. Wolters VM & Wijmenga C (2008). Genetic background of celiac disease and its clinical implications. *Am J of Gastro* 103(1): 190–195.
4. Abu Zekry, M Kryszak, D Diab, M Catassi C & Fasano A (2008). Prevalence of celiac disease in

- egyptian children disputes the east west agriculture-dependent spread of the disease. *J of Pedi Gastro & Nut* 47(2): 136–140.
5. Jong KD, Jaddoe JC, Uitterlinden VWV, Steegers AG, Willemsen EAP, Hofman SP, Hooijkaas H & Moll, HA. (2013) Levels of antibodies against tissue transglutaminase during pregnancy are associated with reduced fetal weight and birth weight. *Gastro* 144(4): 726–735
 6. Gursoy S, Guven K, Simsek T, Yurci A, Torun E, Koc N et al. (2005). The prevalence of unrecognized adult celiac disease in Central Anatolia. *J of Clin Gastro* 39(6): 508–511.
 7. Sacchetti L, Ferrajolo A, Salerno G, Esposito P, Lofrano MM, Oriani G et al. (1996) Diagnostic value of various serum antibodies detected by diverse methods in childhood celiac disease. *Clin Chem* 42(11): 1838–1842.
 8. Tursi A, Giorgetti G, Brandimarte G, Rubino E, Lombardi D & Gasbarrini G. (2001) Prevalence and clinical presentation of subclinical/silent celiac disease in adults: an analysis on a 12-year observation. *Hepato-Gastro* 48(38): 462–464.
 9. Biagi F & Corazza GR. (2002) Clinical features of coeliac disease. *Dig & Liver Dis* 34(3): 225–228.
 10. Tursi A, Brandimarte G & Giorgetti GM (2003) Prevalence of Antitissue Transglutaminase Antibodies in Different Degrees of Intestinal Damage in Celiac Disease. *J of clin Gastro* 36(3): 219–221.
 11. Biagi F, Ellis HJ, Yiannakou JY, Brusco G, Swift GL, Smith PM et al. (1999) Tissue transglutaminase antibodies in celiac disease. *The American J of Gastro* 94(8): 2187–2192.
 12. Sblattero D, Berti I, Trevisiol C, Marzari R, Tommasini A & Bradbury A et al. (2000) Human recombinant tissue transglutaminase ELISA: an innovative diagnostic assay for celiac disease. *The American J of Gastro* 95(5): 1253–1257.
 13. Husby S, Koletzko S, Korponay-Szabó I, Kurppa K, Mearin ML & Ribes-Koninckx C et al. (2020) European society paediatric gastroenterology, hepatology and nutrition guidelines for diagnosing coeliac disease 2020. *J of Pedi Gastro and Nut* 70(1): 141–156.
 14. Saberi-firouzi M, Omrani GR, Nejabat M & Mehrabani D (2008) Prevalence of Celiac Disease in Shiraz, Southern Iran. *Offi J of the Saud Gastro Assoc* 14(3): 135–138.
 15. Akbari MR, Khani AM, Fakheri H, Zahedi MJ, Shahbazkhani B & Nouraie M et al. (2006) Screening of the adult population in Iran for coeliac disease: comparison of the tissue-transglutaminase antibody and anti-endomysial antibody tests. *Euro J of Gastro & Hepato* 18(11): 1181–1186.
 16. Tumer L, Hasanoglu A & Aybay C. (2001) Endomysium antibodies in the diagnosis of celiac disease in short-statured children with no gastrointestinal symptoms. *Pedia Interna : Offi J of the Japan Pediatric Soc* 43(1): 71–73.
 17. Jamila, Kiani RA, Ahmed I, Yousafzai JK & Mehmood W et al. (2018) Celiac Disease in Different Age Groups and Gender in Pakistan. *J of Rawal Med colleg* 22 (3): 244–247.
 18. Marine M, Farre C, Alsina M, Vilar P, Cortijo M & Salas A et al. (2011). The prevalence of coeliac disease is significantly higher in children compared with adults. *Alimen Pharma & Therap* 33 (4): 477–486.
 19. Gillett HR, Cauch-Dudek K, Healthcote EJL & Freeman HJ. (2000) Prevalence of IgA antibodies to endomysium and tissue transglutaminase in primary biliary cirrhosis. *Cana J of Gastro & Hepat* 14(8): 672–675.